What one share of Immatics holds
We are a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities.
Immatics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$1.82 |
|---|---|
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$1.69 |
| Cash and investments | $3.03 |
| Book value | $4.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$1.12 | $0.02 | $0.72 | — | −$0.32 |
| 2019 | — | −$1.07 | $0.07 | $2.33 | — | −$1.42 |
| 2020 | — | −$5.02 | $0.18 | −$2.09 | — | $1.70 |
| 2021 | — | −$1.76 | $0.10 | −$1.69 | — | $0.43 |
| 2022 | — | $0.42 | $0.09 | $1.44 | — | $2.84 |
| 2023 | — | −$1.27 | $0.41 | −$0.17 | — | $2.84 |
| 2024 | — | $0.15 | $0.16 | −$1.77 | — | $4.90 |
| 2025 | — | −$1.82 | $0.06 | −$1.69 | — | $4.24 |
Common questions about Immatics
How much does one share of Immatics earn?
Over its latest fiscal year, Immatics lost $1.82 for each share.
Does Immatics pay a dividend?
Immatics didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Immatics’s book value per share?
Immatics’s book value is $4.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Immatics have?
Each share of Immatics has $3.03 of cash and investments, as of December 31, 2025.
What is Immatics’s free cash flow per share?
−$1.69 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Immatics bought back shares?
Immatics’s share count rose about 270% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.